ArticleJournal of biological engineering2026
Precision Fc remodeling via glycosylation-competent CHO display enables ultra-selective FcγRIIIa targeting and enhanced antitumor activity.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diversity and Bioprospection of Functional Proteins from Sea AnemoneMarine drugs · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundImproving tumor cell clearance by therapeutic antibodies remains a translational bottleneck because wild-type IgG1 Fc typically elicits suboptimal NK cell–mediated antibody-dependent cellular cytotoxicity (ADCC), necessitating Fc engineering to enhance activating FcγR engagement while preserving antigen specificity and manufacturability. FcγRIIIa (CD16A) is the principal activating receptor on NK cells, and its clinical relevance is underscored by the FCGR3A-158V/F polymorphism, which modulates IgG1 Fc affinity and therapeutic response. Because FcγRIIIa engagement critically depends on Fc glycosylation, microbial display platforms lacking mammalian glycan processing are limited in capturing Fc–FcγRIIIa energetics and selectivity.
resultsWe developed a glycosylation-integrated Fc engineering platform using CHO surface display to screen glycosylated Fc libraries in a post-translationally accurate context. Multiparameter flow-cytometric selection with FcγRIIIa binding and FcγRIIb counter-screening enabled iterative isolation of PS-series Fc variants with ultra-selective, allotype-compatible FcγRIIIa recognition. Lead variants achieved 262-fold (158V) and 497-fold (158F) FcγRIIIa affinity gains while reducing FcγRIIb binding by up to 4.2-fold, expanding activating-to-inhibitory selectivity up to 2,096. This exceeded clinically deployed FcγRIIIa-enhancing Fc variants by 525-fold and 108-fold, respectively, in activating-to-inhibitory selectivity, compared with DE (S239D/I332E; used in tafasitamab) and VLPLL (L235V/F243L/R292P/Y300L/P396L; used in margetuximab). When grafted onto trastuzumab, PS variants enhanced NK cytotoxicity and improved tumor control in a trastuzumab-refractory xenograft model. Modular transfer to cetuximab and rituximab also increased cytotoxic activity.
conclusionsThis study establishes a glycosylation-integrated CHO display platform for precision FcγRIIIa-targeted Fc engineering, generating modular effector domains with broad allotype compatibility, minimal FcγRIIb binding, and robust therapeutic potential in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.